Kubo Naoki, Harada Taishi, Anai Satoshi, Otsubo Kohei, Yoneshima Yasuto, Ijichi Kayo, Koga Takaomi, Takayama Koichi, Nakanishi Yoichi
Research Institute for Disease of the Chest, Graduate School of Medical Sciences, Kyushu University, Japan.
Intern Med. 2012;51(17):2399-401. doi: 10.2169/internalmedicine.51.7599. Epub 2012 Sep 1.
A 26-year-old man with unresectable inflammatory myofibroblastic tumor (IMT) presented with multiple metastases in the thoracic vertebra and lymph nodes as detected by positron emission tomography (PET) received chemotherapy with carboplatin plus paclitaxel. After three cycles of chemotherapy, fluorine-18-fluorodeoxyglucose (FDG)-PET/CT revealed tumor regression and significant reduction of FDG uptake in all lesions. The patient received six cycles of chemotherapy without any severe adverse event, and there was no sign of disease progression for seven months. This regimen is well tolerated and may be considered the treatment of choice for unresectable IMT.
一名26岁患有不可切除炎性肌纤维母细胞瘤（IMT）的男性患者，正电子发射断层扫描（PET）检测显示其胸椎和淋巴结有多处转移，接受了卡铂联合紫杉醇化疗。三个周期化疗后，氟-18-氟脱氧葡萄糖（FDG）-PET/CT显示肿瘤消退，所有病灶的FDG摄取显著降低。该患者接受了六个周期化疗，未出现任何严重不良事件，且七个月内无疾病进展迹象。该方案耐受性良好，可被视为不可切除IMT的首选治疗方案。
